Shanghai Jiao Tong University School of Medicine

Junshi Biosciences Presents 11 Clinical Trials of Toripalimab at the ESMO Congress 2023

Retrieved on: 
Friday, October 27, 2023

At the ESMO Congress 2023, Junshi Bioscience showcased a total of 11 clinical trials involving the groundbreaking immune-oncology drug, toripalimab (anti-PD-1 monoclonal antibody), in the forms of 1 late-breaking abstract, 2 proffered paper oral presentations, and 8 posters.

Key Points: 
  • At the ESMO Congress 2023, Junshi Bioscience showcased a total of 11 clinical trials involving the groundbreaking immune-oncology drug, toripalimab (anti-PD-1 monoclonal antibody), in the forms of 1 late-breaking abstract, 2 proffered paper oral presentations, and 8 posters.
  • “This year’s ESMO Congress highlighted the most recent results from 11 clinical studies conducted with our core product, toripalimab,” said Dr. Jianjun ZOU, Global Research and Development President of Junshi Biosciences.
  • Study findings were unveiled for the first time during a proffered paper session at the ESMO Congress.
  • In terms of safety, toripalimab combined with chemotherapy has a manageable safety profile and no new safety signals were identified.

Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab

Retrieved on: 
Wednesday, July 12, 2023

Therefore, the need for new treatment options is more urgent for patients with medium and high-risk advanced RCC compared to low-risk patients.

Key Points: 
  • Therefore, the need for new treatment options is more urgent for patients with medium and high-risk advanced RCC compared to low-risk patients.
  • This supplemental new drug application is mainly based on the RENOTORCH study (NCT04394975).
  • The safety profile of toripalimab in the study was consistent with known risks, and no new safety signals were identified.
  • Dr. Jianjun ZOU, the Global Research and Development President of Junshi Biosciences, expressed her enthusiasm regarding the acceptance of this application.

Junshi Biosciences Announces NEJM Publication of Results of Phase 3 Study of VV116 Versus PAXLOVID for Adults at High Risk for Progression to Severe COVID-19

Retrieved on: 
Thursday, December 29, 2022

It is the first time that NEJM published the clinical trial results of China-developed anti-SARS-CoV-2 drug.

Key Points: 
  • It is the first time that NEJM published the clinical trial results of China-developed anti-SARS-CoV-2 drug.
  • The results indicated that the primary endpoint of the study realized the designed noninferiority endpoint, and VV116 group had a shorter time to sustained clinical recovery with less safety concerns as compared with PAXLOVID.
  • Finally, a total of 771 patients (Full Analysis Set, FAS) were treated with VV116 (n = 384) or PAXLOVID (n = 387).
  • The incidence of AEs in VV116 group was lower than that in the PAXLOVID group (all-grade AEs: 67.4% vs. 77.3%, Grade 3 or 4 AE: 2.6% vs. 5.7%).

CARsgen Appoints Dr. Hua Jiang as Executive Director

Retrieved on: 
Tuesday, August 2, 2022

SHANGHAI, Aug. 2, 2022 /PRNewswire/ --CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that Dr. Hua Jiang ("Dr. Jiang") has been appointed as Executive Director of the Company.

Key Points: 
  • SHANGHAI, Aug. 2, 2022 /PRNewswire/ --CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that Dr. Hua Jiang ("Dr. Jiang") has been appointed as Executive Director of the Company.
  • Dr. Jiang has contributed significantly to the early research, technology platform development, and innovative products development in CARsgen.
  • Dr. Zonghai Li, Founder, Chairman of the Board, Chief Executive Officer, and Chief Scientific Officer of CARsgen, added, "On behalf of the Board, I would like to congratulate Dr. Jiang to be appointed as the Executive Director.
  • Dr. Hua Jiang, Executive Director, Vice President of Early Discovery of CARsgen, said, "I am pleased to become a member of the Board and would like to thank the Board for the recognition and trust.

Innovent Will Present Clinical Data of IBI110 (anti-LAG-3 monoclonal antibody) and Other Multiple Trials at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Monday, May 16, 2022

Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, autoimmune, metabolic, ophthalmologyand other major diseases.

Key Points: 
  • Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, autoimmune, metabolic, ophthalmologyand other major diseases.
  • On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.
  • Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities.
  • Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts.

IOF Announces First International Orthodontic Symposium

Retrieved on: 
Thursday, May 12, 2022

The Symposium Will Unveil the Future of Orthodontics for the Next Decade

Key Points: 
  • Hong Kong, China--(Newsfile Corp. - May 12, 2022) - The 1st IOF International Orthodontic Symposium & Inaugural Meeting will be held from June,3rd ~ 5th, 2022.
  • IOF (International Orthodontics Foundation) is an international academic organization in orthodontics and related fields.
  • IOF (International Orthodontics Foundation) is an international academic organization in orthodontics and related fields.
  • Additionally, the IOF will be officially inaugurated during the symposium and the first round of applications for the IOF Research Grants will be launched.

Tai Chi Training Can Effectively Improve Parkinson's Disease and Mild Cognitive Impairment

Retrieved on: 
Thursday, March 31, 2022

This is also the scientific research achievements of the two philanthropic projects, "Tai Chi Adjuvant Therapy for Parkinson's Disease" and "Tai Chi Training Delays Alzheimer's Disease", jointly launched by Fosun Foundation, Sino Taiji and the Neurology Department of Ruijin Hospital.

Key Points: 
  • This is also the scientific research achievements of the two philanthropic projects, "Tai Chi Adjuvant Therapy for Parkinson's Disease" and "Tai Chi Training Delays Alzheimer's Disease", jointly launched by Fosun Foundation, Sino Taiji and the Neurology Department of Ruijin Hospital.
  • Besides, keepingTai Chi combined with cognitive training for two years showed delayed decline in global cognition and memory than withdrawing Tai Chi combined with cognitive training.
  • By exploring the mechanism of long-term Tai Chi training in improving motor symptom in patients with Parkinson's disease, the research article titled "Mechanisms of motor symptom improvement by long-term Tai Chi training in Parkinson's disease patients" indicates that long-term Tai Chi training can significantly improve motor symptom in patients with Parkinson's disease.
  • In addition, the "Tai Chi Training Delays Alzheimer's Disease" project will launch a 5-year in-depth clinical research to recruit MCI patients in the community, and to explore the effect of longer-term Tai Chi training on MCI patients, helping more patients with MCI to improve their cognitive function and delay the occurrence of Alzheimer disease through charitable Tai Chi training projects.

Eisai Announces New Executive Leadership Team at H3 Biomedicine

Retrieved on: 
Monday, August 30, 2021

WOODCLIFF LAKE, N.J., Aug. 30, 2021 /PRNewswire/ --Eisai today announced that H3 Biomedicine (H3), its cancer genomics-based drug discovery subsidiary company located in Cambridge, Mass., has appointed a new executive leadership team.

Key Points: 
  • WOODCLIFF LAKE, N.J., Aug. 30, 2021 /PRNewswire/ --Eisai today announced that H3 Biomedicine (H3), its cancer genomics-based drug discovery subsidiary company located in Cambridge, Mass., has appointed a new executive leadership team.
  • Ping Zhu, Ph.D., has been named President and Chief Scientific Officer, and will be responsible for the scientific strategy and business direction of H3.
  • Dr. Zhu, who joined H3 in 2012 as Associate Director of Target Discovery & Genomics, most recently held the position of Head of Discovery & Research.
  • H3 Biomedicine Inc., the U.S.-based precision oncology research and development subsidiary of Eisai Co., Ltd., is solely focused on advancing drugs from bench to bedside.